The RESPONSE trial was a pivotal phase 3 study designed to evaluate the efficacy and safety of seladelpar, a selective peroxisome proliferator–activated receptor delta (PPARδ) agonist, in patients with primary biliary cholangitis (PBC) who had an inadequate response to or could not tolerate ursodeoxycholic acid (UDCA). Conducted across 24 countries, the trial enrolled 193 patients who were randomized 2:1 to receive seladelpar (10 mg daily) or placebo, with or without...
The RESPONSE trial was a pivotal phase 3 study designed to evaluate the efficacy and safety of seladelpar, a selective peroxisome proliferator–activated receptor delta (PPARδ) agonist, in patients with primary biliary cholangitis (PBC) who had an inadequate response to or could not tolerate ursodeoxycholic acid (UDCA). Conducted across 24 countries, the trial enrolled 193 patients who were randomized 2:1 to receive seladelpar (10 mg daily) or placebo, with or without UDCA background therapy, over 12 months.
The primary endpoint was achieving a biochemical response, defined as alkaline phosphatase (ALP) <1.67× upper limit of normal (ULN), ≥15% reduction from baseline, and normal total bilirubin at month 12. Seladelpar demonstrated superior efficacy, achieving a biochemical response in 61.7% of patients versus 20.0% in the placebo group (P<0.001). Additionally, 25% of seladelpar-treated patients achieved full ALP normalization compared to 0% with placebo (P<0.001), indicating significant disease control. Seladelpar also reduced mean ALP levels by 42.4%, compared to only 4.3% with placebo, reflecting strong anticholestatic activity.
Secondary endpoints included improvements in pruritus and quality of life. Among patients with moderate-to-severe itching, seladelpar reduced pruritus scores by −3.2 points versus −1.7 with placebo (P=0.005), providing clinically meaningful relief. Patients also reported improvements in fatigue, itch, and social functioning on quality-of-life measures.
Seladelpar exhibited a favorable safety profile, with adverse events mostly mild and similar between groups. Unlike obeticholic acid, seladelpar improved itch and had a cleaner safety profile, establishing it as a potentially superior second-line therapy for PBC.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.